drugset / Trial / NCT02573896
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
Phase 1
Active not recruiting
13 enrolled
New Approaches to Neuroblastoma Therapy Consortium
Nationwide Children's Hospital · collabUnited Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for treatment of children with refractory or recurrent neuroblastoma.
Timeline
- Start
- 2019-01-14
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dinutuximab | Monoclonal antibody | 17.5 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 25 mg/m2 | Oral |
| Subject | TROCULEUCEL | Cell therapy | — | Intravenous |